arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

CG Oncology, Inc.

CGON Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$74.67
Today
as of Sep 4, 16:47 ET
Last 30 days +2.82% Jul 28 → Sep 04
$68.20 $71.55 $74.90 $78.25 $81.60 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$73.02
High
$74.88
Low
$72.87
Volume
$282,519
Avg Vol
$1M
Mkt Cap
$6.9B
P/E (TTM)
—
Beta
—
52w High
$80.97
52w Low
$32.08
Div Yield
—
Shares Out
$88M

Recent Press Releases & News last 60 days · 2 items

Sep 3 · 13:06 Simply Wall St.
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run
Aug 6 · 13:50 Zacks
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

Overview

52-week range
$32
$81
87% of range
Avg surprise (last 3)
-16.0%
Avg reaction (last 2)
-1.6%
50% positive
Latest IV / EM
91%
EM ±14.2% · $75 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-4.00$-3.07$-2.14$-1.21$-0.28 Actual $-3.22Actual $-3.93Actual $-4.00Actual $-0.36Actual $-0.28Actual $-0.30Actual $-0.45Est $-0.39Actual $-0.54Est $-0.49Actual $-0.57Actual $-0.71Est $-0.58Actual $-0.90 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-79M$-59M$-39M$-18M$2M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.90 — — — — financials
Fri May 8, 2026Mar/2026 $-0.71 $-0.58 -22.4% -57.8% +0.6% earnings
Tue Sep 30, 2025Sep 2025 $-0.57 — — — — financials
Fri Aug 8, 2025Jun/2025 $-0.54 $-0.49 -10.2% — — earnings
Tue May 13, 2025Mar/2025 $-0.45 $-0.39 -15.4% — -3.9% earnings
Mon Sep 30, 2024Sep 2024 $-0.30 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.28 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.36 — — — — financials
Sat Sep 30, 2023Sep 2023 $-4.00 — — — — financials
Fri Jun 30, 2023Jun 2023 $-3.93 — — — — financials
Fri Mar 31, 2023Mar 2023 $-3.22 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1M$1M—$2M$0$52,000—$43,000
Cost of revenue————————
Gross profit————————
Operating income$-86M$-66M—$-51M$-49M$-42M—$-28M
Net income$-79M$-60M—$-44M$-41M$-34M—$-20M
EPS (diluted)$-0.90$-0.71—$-0.57$-0.54$-0.45—$-0.30

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$20M$34M$32M$45M$15M$41M$257M$43M
Inventory$1M$1M$2M$2M——$0—
Total current assets$1.05B$1.10B$759M$696M$673M$701M$754M$552M
Total assets$1.09B$1.14B$792M$730M$701M$728M$755M$552M
Long-term debt$3M$3M$3M$3M——$0—
Total liabilities$57M$43M$39M$42M$31M$23M$21M$16M
Total equity$1.03B$1.09B$753M$688M$670M$705M$733M$537M

Implied volatility — last 90 days

65%108%151%194%237% Jun 07 — IV 180% · EM ±24.9%Jun 08 — IV 184% · EM ±24.3%Jun 09 — IV 163% · EM ±20.5%Jun 10 — IV 170% · EM ±20.0%Jun 11 — IV 173% · EM ±19.1%Jun 12 — IV 150% · EM ±15.4%Jun 15 — IV 238% · EM ±17.2%Jun 16 — IV 173% · EM ±10.2%Jun 17 — IV 236% · EM ±9.8%Jun 19 — IV 123% · EM ±27.3%Jun 22 — IV 108% · EM ±22.5%Jun 23 — IV 105% · EM ±21.5%Jun 24 — IV 110% · EM ±22.0%Jun 25 — IV 107% · EM ±21.0%Jun 26 — IV 120% · EM ±23.0%Jun 29 — IV 118% · EM ±20.8%Jun 30 — IV 122% · EM ±21.0%Jul 01 — IV 119% · EM ±19.9%Jul 02 — IV 123% · EM ±19.9%Jul 03 — IV 127% · EM ±19.9%Jul 06 — IV 120% · EM ±16.6%Jul 07 — IV 114% · EM ±15.1%Jul 08 — IV 91% · EM ±11.5%Jul 09 — IV 89% · EM ±10.6%Jul 10 — IV 78% · EM ±8.6%Jul 13 — IV 122% · EM ±10.2%Jul 14 — IV 141% · EM ±10.2%Jul 15 — IV 114% · EM ±6.7%Jul 16 — IV 191% · EM ±8.0%Jul 20 — IV 97% · EM ±22.8%Jul 21 — IV 94% · EM ±21.9%Jul 22 — IV 97% · EM ±22.1%Jul 23 — IV 108% · EM ±24.2%Jul 24 — IV 96% · EM ±21.2%Jul 27 — IV 105% · EM ±21.8%Jul 28 — IV 95% · EM ±19.3%Jul 29 — IV 108% · EM ±21.7%Jul 30 — IV 100% · EM ±19.5%Jul 31 — IV 108% · EM ±20.6%Aug 03 — IV 119% · EM ±21.1%Aug 04 — IV 109% · EM ±18.8%Aug 05 — IV 114% · EM ±19.1%Aug 06 — IV 82% · EM ±13.2%Aug 07 — IV 66% · EM ±10.3%Aug 10 — IV 70% · EM ±9.7%Aug 11 — IV 67% · EM ±8.8%Aug 12 — IV 77% · EM ±9.6%Aug 13 — IV 78% · EM ±9.3%Aug 14 — IV 69% · EM ±7.7%Aug 17 — IV 97% · EM ±8.1%Aug 18 — IV 85% · EM ±6.2%Aug 19 — IV 110% · EM ±6.5%Aug 20 — IV 167% · EM ±7.0%Aug 24 — IV 88% · EM ±18.4%Aug 25 — IV 74% · EM ±15.1%Aug 26 — IV 81% · EM ±16.3%Aug 27 — IV 76% · EM ±14.8%Aug 28 — IV 80% · EM ±15.3%Aug 31 — IV 96% · EM ±17.0%Sep 01 — IV 89% · EM ±15.4%Sep 02 — IV 92% · EM ±15.4%Sep 03 — IV 98% · EM ±15.9%Sep 04 — IV 91% · EM ±14.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in